Relmada Therapeutics Inc. Insider Trading

RLMD

⊜ Compare

Last 12 months

Insiders bought $4.03M on the open market and sold nothing.

Net open-market

+$4.03M

8 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

4 / 0

executives and directors

Last open-market buy

Sep 2026

Sep 10, 2026

Get an email when RLMD's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 9 – 10	Maged Shenouda Chief Financial Officer	Bought 2 parts	200,000	$4.22 average	844K	25%	Form 4
Sep 9 – 10	Sergio Traversa Chief Executive Officer	Bought 2 parts	200,000	$4.14 average	828K	15%	Form 4
Dec 15, 2025	Sergio Traversa Chief Executive Officer	Bought	27,500	$4.12	113K	2.2%	Form 4
Dec 15, 2025	Maged Shenouda Chief Financial Officer	Bought	11,665	$4.12	48K	1.5%	Form 4
Nov 5, 2025	Chuck Ence CAO and COO	Bought	136,000	$2.20	299K	51%	Form 4
Nov 5, 2025	Sergio Traversa Chief Executive Officer	Bought	272,500	$2.20	600K	27%	Form 4
Nov 5, 2025	Maged Shenouda Chief Financial Officer	Bought	500,000	$2.20	$1.1M	173%	Form 4
Nov 5, 2025	Paul Edward Kelly Chief Operating Officer	Bought	90,000	$2.20	198K	22%	Form 4
Aug 26, 2025 – Aug 28, 2025	Sergio Traversa Chief Executive Officer	Bought 3 parts	265,976	$0.67 average	178K	36%	Form 4
May 16, 2025 – May 20, 2025	Maged Shenouda Chief Financial Officer	Bought 3 parts	200,000	$0.49 average	97K	226%	Form 4
May 16, 2025 – May 20, 2025	Sergio Traversa Chief Executive Officer	Bought 3 parts	350,000	$0.50 average	175K	91%	Form 4
May 16, 2025	Paul Edward Kelly Chief Operating Officer	Bought	200,000	$0.43	86K	94%	Form 4
May 16, 2025	Chuck Ence CA and CO	Bought	228,961	$0.45	103K	588%	Form 4

Sep 9 – 10
Maged Shenouda
Chief Financial Officer · bought 200,000 at avg $4.22
844K
25% of stake
Sep 9 – 10
Sergio Traversa
Chief Executive Officer · bought 200,000 at avg $4.14
828K
15% of stake
Dec 15, 2025
Sergio Traversa
Chief Executive Officer · bought 27,500 at $4.12
113K
2.2% of stake
Dec 15, 2025
Maged Shenouda
Chief Financial Officer · bought 11,665 at $4.12
48K
1.5% of stake
Nov 5, 2025
Chuck Ence
CAO and COO · bought 136,000 at $2.20
299K
51% of stake
Nov 5, 2025
Sergio Traversa
Chief Executive Officer · bought 272,500 at $2.20
600K
27% of stake
Nov 5, 2025
Maged Shenouda
Chief Financial Officer · bought 500,000 at $2.20
$1.1M
173% of stake
Nov 5, 2025
Paul Edward Kelly
Chief Operating Officer · bought 90,000 at $2.20
198K
22% of stake
Aug 26, 2025 – Aug 28, 2025
Sergio Traversa
Chief Executive Officer · bought 265,976 at avg $0.67
178K
36% of stake
May 16, 2025 – May 20, 2025
Maged Shenouda
Chief Financial Officer · bought 200,000 at avg $0.49
97K
226% of stake
May 16, 2025 – May 20, 2025
Sergio Traversa
Chief Executive Officer · bought 350,000 at avg $0.50
175K
91% of stake
May 16, 2025
Paul Edward Kelly
Chief Operating Officer · bought 200,000 at $0.43
86K
94% of stake
May 16, 2025
Chuck Ence
CA and CO · bought 228,961 at $0.45
103K
588% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch RLMD, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with RLMD

CompareIntrinsic value

VRCAVerrica Pharmaceuticals Inc.

$3.46+5.02%40

CTMXCytomX Therapeutics Inc.

$2.35+7.80%10

KRROKorro Bio Inc.

$16.62+4.79%10

WHWKWhitehawk Therapeutics, Inc.

$3.15+1.61%10

FHTXFoghorn Therapeutics Inc.

$2.10-1.41%40

NATRNature's Sunshine Products Inc.

$12.84+6.38%70

EVMNEvommune, Inc.

$6.04+1.68%35

VSTMVerastem Inc.

$9.85+0.82%40

Held by ETFs

RLMD is in 9 US ETFs. The largest of them, with RLMD's weight in each:

Spot a number that looks wrong? Check it in RLMD's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RLMD

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.